pLKO.1 shMTH1-2 Citations (3)

Originally described in: Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence.
Rai P, Onder TT, Young JJ, McFaline JL, Pang B, Dedon PC, Weinberg RA Proc Natl Acad Sci U S A. 2009 Jan 6. 106(1):169-74. PubMed Journal

---

Articles Citing pLKO.1 shMTH1-2

Articles
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Stromberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G. Nature. 2014 Apr 10;508(7495):222-7. doi: 10.1038/nature13194. Epub 2014 Apr 2. PubMed
TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. Moukengue B, Brown HK, Charrier C, Battaglia S, Baud'huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F. EBioMedicine. 2020 Mar;53:102704. doi: 10.1016/j.ebiom.2020.102704. Epub 2020 Mar 7. PubMed
METTL3 promotes cell-cycle progression via activation of transcriptional elongation. Akcaoz-Alasar A, Wang Y, Li H, Ostapenko D, Ramirez Parrado CA, Villalobos D, Li W, Boddu PC, Nguyen AH, Li H, Perez-Pepe M, Darnat P, Akgul B, Pillai MM, Liu Y, Kabeche L, Alarcon CR. Mol Cell. 2026 Aug 20;86(16):3213-3222.e5. doi: 10.1016/j.molcel.2026.07.011. Epub 2026 Jul 31. PubMed

If you have published an article using this material, please email us at to have your article added to this page.